Lupin Expands US Inhalation Business With Two Sunovion Brands
Indian Firm Pays $75m For US Rights To Respiratory Brands Brovana And Xopenex HFA
Executive Summary
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
You may also be interested in...
Gavaris Leads Lupin In US Ahead Of Core Spiriva Strategy
Lupin praised the “strong pharma and biotech experience” of former Hikma executive Spiro Gavaris after appointing him to head up the firm’s US generics unit.
Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise
Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise